Table 1.
Baseline characteristics.
Fig 1.
Relative change of LDL cholesterol after PCSK9 inhibitor therapy.
Therapy with PCSK9 inhibitors resulted in an overall LDL cholesterol reduction of 40%. As can be seen, the LDL cholesterol levels of individual patients (X-axis) ranged between +26% and -66% when comparing LDL levels after PCSK9 inhibitor therapy to baseline.
Table 2.
Treatment effect of PCSK9 inhibitors.
Fig 2.
Effects of PCSK9 on dyslipidaemia and the vascular system.
By inhibiting the binding of PCSK9 to LDL and LDL receptors (LDLr) more LDLr are expressed on the surface of hepatocytes and thus lead to decreased levels of circulating LDL Cholesterol. Inhibiting the effect of PCSK9 on LDL oxidation, inflammation and prothrombosis treatment could have an effect on coronary plaque stabilisation.